Showing results (1501-1510 of 2,739) with videos related to
Sort By:
Pageof 274
Pharmacogenomics|December 11, 2012
Genome-wide transcriptomic variations of human lymphoblastoid cell lines: insights from pairwise gene-expression correlationsMarc Vincent, Keren Oved, Ayelet Morag, et al.Pharmacogenomics|December 11, 2012
Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patientsAlga S Ramos, Richard L Seip, Giselle Rivera-Miranda, et al.Pharmacogenomics|December 11, 2012
Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiencyJulie Autmizguine, Maja Krajinovic, Julie Rousseau, et al.Pharmacogenomics|December 11, 2012
Breaking free from the chains of pathway annotation: de novo pathway discovery for the analysis of disease processesBenjamin Lehne, Thomas SchlittPharmacogenomics|December 21, 2012
Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expressionPengcheng Shi, Jie Zha, Xutao Guo, et al.Pharmacogenomics|December 21, 2012
Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsyYogita Ghodke Puranik, Angela K Birnbaum, Susan E Marino, et al.Pharmacogenomics|December 21, 2012
Towards a balanced value business model for personalized medicine: an outlookChristof Koelsch, Joanna Przewrocka, Peter KeelingPharmacogenomics|January 19, 2013
CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycinLaure Elens, Annemieke Nieuweboer, Stephen J Clarke, et al.Pharmacogenomics|January 19, 2013
An evaluation of pharmacists' expectations towards pharmacogenomicsSimon de Denus, Nathalie Letarte, Thierry Hurlimann, et al.Pharmacogenomics|January 19, 2013
Regulatory perspective on remaining challenges for utilization of pharmacogenomics-guided drug developmentsYasuto Otsubo, Akihiro Ishiguro, Yoshiaki UyamaPageof 274